Singapore, April 18 -- Mabwell, a China-based innovation-driven biopharmaceutical company with a fully integrated industry chain, has established a licensing and commercialisation agreement with a strategic business partner in Malaysia for its Denosumab biosimilar products MAILISHU (a biosimilar of Prolia(R)) and MAIWEIJIAN (a biosimilar of Xgeva(R)).

Under the agreement, the partner is responsible for the registration and commercialisation of the products in Malaysia, while Mabwell is responsible for the development, production and commercial supply for the products.

Malaysia has a population of approximately 35.97 million, with a GDP at a leading level in Southeast Asia. As a full member of PIC/S, Malaysia boasts the most mature ...